Rick Simpson Oil (RSO) Bethel Census Area, Alaska: OilWell Cannabis-aa Mamterillermi Pillraq

Bethel Census Area-aami piyugngaluten pitekluku yuukicetaar. Oregon-aam qanrusngaq qanrusngamun pivkaq pivarvim kankumek. Uksumi qanikcaq yugmun acaaq qanruteksailngamun kinguqlirmun kinguqlirmek. Medicine-aq tuntussiyaq aulavigmi kinguartellmi pinarqellria. Medevac tekitaq tamarmi umyuarteqaqaq, specialist care-aq tekitaq cungagtarqumek. Pamaggaraa maavet aturrluta, tamatumun ella assirtuq. Taugam OilWell Cannabis-aq man’a teq’uq arulaiq: legal, multi-cannabinoid RSO qaneryaraallratun Rick Simpson-aam qanrutkaa atularyaraulliniluni, taringarkaugaq yuut makuneng yuutun ayuqngakegcimaluni piciryaraitgun.

Man’a “hype” nakuuyuq. Piciatun yuutun evidence-aq piyaraitgun RSO-yaraq nutaan-llu atulliniluni assiilnguq — Bethel Census Area-aam yulirtetun piyaraitgun, Kuskokwim imarpigmi tuntumek qanrusngamun Yukon imarpigmi neqpiallerkun. Bethel-aami, Kwethluk-aami, Napakiak-aami, ak’a qanrusngam qulen 34 nayuramtenun, RSO-wa tarrnaq, nallunritarkaun, wangkutun atullernun-llu legal-amek aterluta ilaani.

Rick Simpson Ayaullra: RSO-wa Aanqigcistetun

Rick Simpson-aq doctor-aanqigciit-llu scientist-aanqigciit-llu. Nova Scotia-aam power engineer-aqaaq — blue-collar tradesman-aq. 1997-aami Moncton, Canada-aami pivarviim acaan iqsarpaa, scaffolding-mek. Atiin qasaaq tinnitus, dizziness, post-concussion symptom-aat pivarvim atausrngatai aulatuyutngatelliniluteng. Medicine-aat aulatumek akyuussiyaunateng. Cannabis-aq qanrutellra doctor-aq qanrusnganrulluni .

Bethel Census Area-aami taringnaqaa? Makuneng yuulluta friends-put, family-put makuneng ayuqengait: fishing, construction, transportation-aaq ayuqaq aulatumek akyuussiyaunateng; doctor-aat cannabis-am qanruskanrulluki “watua waten amqigteksaiteqaqan” aulatulluku. Man’a qalaliuq tamarmi piyugngayugnaqsaaq, Bethel-aami nayuramun yaaqvanun-llu.

Simpson-aq 1974-aam NIH-funded study-aq Medical College of Virginia-aam tarrnarqellria THC-wa mouse-aam tumait elliuqeksuunatelliniluku, nalluyagutaq. Man’a RSO-yaraa qanrutkaa aanngamun, ayuqailluni controlled human trials-aaq nallunriqeksuitellra . 2003-aami Simpson-aq qanellra basal cell carcinoma pivallermini arm-mi three bumps-aani concentrated cannabis oil-aq atuliqluku four days-aami ellinuiluni. Biopsy-aq nallunriqeksuitellra. Independent medical verification-aq nallunriqeksuitellra. Peer-reviewed documentation-aq nallunriqeksuitellra. Taugaq man’a personal testimony-aq RSO-yaraa aanngamun .

Qalarcaraq aturarkauqsaaq: Simpson-aq account-aq personal testimony-aq, medical evidence-aanqigciit. Historically significant-aq global movement-aq aanngamun, taugaq clinical proof-aq akeqcaayuituq. Bethel Census Area-aami yuut serious health decisions-aq piyaraitgun man’a distinction-aq taringarcaraa assiqsaaq.

The Crusade: RSO-wa Global Movement-aq Aanngamun

2003-aam experience-aaneng Simpson-aq concentrated cannabis oil-aq piyaraitgun piyukicetaar. Maccan, Nova Scotia-aami community-aani cancer patients-aaq-llu community-aani qanruteksaitelluni piluku. Cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia-aaq-llu yuutun Bethel Census Area-aami makuneng yuutun aulayuataar .

2005-aami Run From The Cure documentary-aq Simpson-aq story-aq global-aq piluku. Online-aq qanruteksaitelluni free, cannabis communities worldwide-aq foundational-aq piluku. Bethel Census Area-aami yuut makuneng concentrated cannabis oil-aq medicine-aq taringtaq aanngamun documentary-aq aanngamun .

Tauguurutauq Simpson-aq advocacy-aq legal conflict-aq aanngamun. Royal Canadian Mounted Police-aq property-aqaq 2005-aami-llu 2009-aami-llu raid-arput. Cultivation, possession, trafficking-aaq charges-aani. Canada-mek Europe-aaq atulluni Croatia-aami Netherlands-aami-llu advocation-aq pilluni . Phoenix Tears 2012-aami publisher-aq, phoenixtears.ca platform-aq piluku .

Public career-aani Simpson-aq RSO-wa cancer cure-yaarqaaq pilluku. Pharmaceutical companies, government agencies, medical institutions-aq knowledge-aq suppress-arkaulriit. Work-aqaan institutional corruption-aq fight-aq pilluku .

Qalarcaraq aturarkauqsaaq: Simpson-aq conspiratorial worldview-aq early cannabis movement-aq institutional distrust-aq aanngamun. Bethel Census Area-aami yuut healthcare gaps-aq, long wait times-aq, dismissive medical encounters-aq tarrnarqellriit. Tauguurutauq OilWell-aam concerns-aq evidence-aq atulluta atulliniluni, conspiracy theories-aq akeqcaayuunateng.

Traditional RSO Protocol: Simpson-aq 60-Gram, 90-Day Regimen

Simpson-aq core treatment recommendation-aq 60 grams concentrated cannabis oil-aq approximately 90 days-aani nangerciq. Qaneryarallra man’a :

Week 1: Half grain of rice-aam size-aam dose-aq (10-15 mg) three times daily. Total daily intake: 30-45 mg.

Weeks 2-5: Dose-aq approximately four days-aani double. THC-aq psychoactive effects-aq tolerance-aq build-aq pilluku. Goal-aam 1 gram (1,000 mg) oil-aq per day, three doses-aani 333 mg each.

Weeks 5-12: 1 gram per day maintain-arkaulluku until 60 grams consumed.

Administration methods: Oral (primary), skin cancers-aani topical, immediate symptom relief-aani inhalation taugaq primary treatment-aanqigciit.

Qalarcaraq aturarkauqsaaq man’a protocol-aq aularyaraitgun:

• Controlled trial validation-aq nallunriqeksuitellra. Randomized controlled trial, cohort study, well-documented case series-aq man’a protocol-aq support-arkaullriit nallunriqeksuitellra .
• Crude, unstandardized material-aq assume-aq. 60-gram quantity-aq single-strain, THC-dominant extract-aq standardized potency-aanqigciit — actual THC content-aq starting material-llu extraction technique-llu vary-arkaulluni.
• Very high THC exposure. Peak dosing-aani traditional RSO-aq approximately 600-900 mg delta-9 THC per day deliver-aq. FDA-approved synthetic THC drug dronabinol-aq typically 2.5-20 mg per day. 30-360x higher dose-aq controlled clinical settings-aani studied-aaneng akeqcaayuituq.
• Real risks at doses. 600-900 mg THC daily consume-aq serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, cannabis use disorder [1][13][14][15].
• Oncology context. Active cancer-aani patients-aq medically complex-aq. Unregulated, unstandardized cannabis oil-aq primary treatment-aq use-aq — potentially proven therapies-aq instead of — harm-aq oil-aq itself-aq extend-arkaulluni.

Bethel Census Area-aami yuut man’a protocol-aq particularly concerning. Region-aani medical oversight limited, emergency services hours away, 600-900 mg THC daily consume-aq medical supervision akeqcaayuunateng dangerous. OilWell-aq approach-aq fundamentally different.

Traditional RSO Aterrluku Atulliniluni Man’a

Traditional RSO-aq Simpson-aq method-aaneng defined, lab specifications-aanqigciit:

Source material: Single high-THC indica strains, unstandardized, availability-llu growing season-llu vary.

Extraction solvent: Naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol — food-grade-aanqigciit. Naphtha-aq benzene, toluene, carcinogens-llu contain. Incomplete solvent purging-aq toxic residues leave [1].

Process: Cannabis-aq solvent-aani soaked, filtered, rice cooker-aani evaporated at temperatures terpenes destroy-arkaulluki THCa THCa-llu fully decarboxylate.

Appearance: Nearly black, tar-like, thick oil strong cannabis odor-llu possible solvent-residual smell-llu.

Cannabinoid profile: THC-dominant (60-90% estimated), fully decarboxylated, minor cannabinoids natural ratios-aanni — uncontrolled, unmeasured, lab-verified-aanqigciit.

Terpene content: Minimal to none. Solvent-llu heat process-aq volatile terpenes destroy, cannabinoid-only product leave despite terpene-rich plant-aq derived.

Standardization and testing: None. Every batch different. Certificate of Analysis nallunriqeksuitellra, cannabinoid quantification nallunriqeksuitellra, contaminant screening nallunriqeksuitellra.

Residual solvent risk: Traditional RSO production-aq finished oil-aqaq potentially harmful solvent residues leave — one of the most significant safety concerns [1].

Bethel Census Area-aami yuut subsistence living-aq practice-aq, traditional plant medicine-aq experience-aq, own medicine make-aq idea-aq resonate. Tauguurutauq traditional RSO-aq solvent safety issues-aq especially relevant. Remote region-aani analytical chemistry equipment access limited, solvent removal verify-aq impossible. Modern extraction methods food-grade ethanol or CO₂ critical improvements.

Evidence: Science Qaneryaraa Atulliniluni

Simpson Aanngamun Atulliniluni

Simpson-aq cannabinoids-aq serious biomedical research area-aq attention draw-aq when world-aq ignoring. Legal cannabis industry-aq conditions create-aq. “RSO” term-aq full-spectrum cannabis extract-aq most recognized name-aq remain. Contributions real and historically significant .

Man’a Aanngamun Qaneryaraq

Simpson-aq cure claims-aq evidence-aq exceed. Patients-aq RSO use-aq proven cancer therapies-aq instead of encourage-aq genuine harm potential carry. Delayed or foregone treatment-aq alternative medicine-aq documented concern .

Institutional positions clear:

• U.S. National Cancer Institute-aq cannabinoid anticancer research-aq lab-llu animal model-aq acknowledge taugaq cannabis-aq cancer treatment-aq endorse nalluniluku .
• FDA-aq cancer-aani cannabis plant product-any approve nalluniluku. Purified CBD (Epidiolex)-lu synthetic THC analogues (dronabinol, nabilone)-lu specific approvals other conditions-aani [1].
• Health Canada-aq RSO-aq cancer-aani approve nalluniluku .
• NCCIH-aq strongest evidence-aq rare epilepsies, chemo nausea, HIV/AIDS appetite — cancer cure-aanqigciit [1].

Bethel Census Area-aami yuut cancer diagnoses-aq face-aq, man’a honesty crucial. Yukon-Kuskokwim Health Corporation-alu Bethel Regional Health Center-alu integrative approaches-aq qanrutkekciqut. RSO education-aq medical care-aq complement; replace nalluniluku. Proven treatment-aq unproven alternatives-aq delay nalluniluku.

OilWell Cannabis: Story-put

OilWell Cannabis-aq Houston, Texas-aami Colin Valencia founded-aq. Colin-aq story-aq McAllen, Texas-aami qakemkun Reynosa, Mexico-aam. McAllen-Reynosa area-aq Borderplex qaneryaraq known, U.S.-Mexico border-aani economically challenged-llu dangerous regions. McAllen-aq vibrant culture-aq limited opportunities retail-llu healthcare-lu. Reynosa-aq industrial hub-aq cartel violence-aani plagued.

Colin-aq childhood McAllen-aami opportunities dangers-llu expose-aq. Qanikcilluni early, risky work-aq border-aq transport-aq items. Best friends-aq makuneng killed prison-aq-llu. Every form of violence-aq faces, streets-aani border-aani-llu. Sixteen-aamik home-aq leave-aq.

Despite dangers, Colin-aq harder substances sell nalluniluku. Cannabis-aq focus-aq, safer more beneficial alternative-aq aulakuni. Traditional cannabis world-aami grow up long before legalization, plant-aq intimately learn while shadows-aani operate. Over time early risky ventures-aq transition-aq legal legitimate business-aq create-aq.

Colin-aq later formally trained software engineer-aq, Baylor College of Medicine-aq custom development work, Texas Medical Center-aani most prestigious medical institutions. Combination-aq — deep cannabis plant knowledge plus medical-grade technical precision — OilWell-aq approach-aq define.

Bentley Story: Everything Aanngamun

Company-aq origin story-aq Bentley atenrilnguq dog-aami. Bentley-aq pet-aanqigciit — family-aq. Bentley-aq seriously ill-aq veterinarians-aq verdict-aq deliver no owner wants: euthanasia only humane option. Bentley-aq back legs-aani paralyzed. Pain medications internal organs destroy-aq. Choice painful prolonged decline-im immediate mercy killing-llu.

Bentley-aq give up nalluniluku. Desperate search alternatives-aani Colin-aq CBD stumble. Rescue worker Jessica-aq ask: “How many tons weed move-aq CBD heard never?” Colin-aq cannabis experience-aq — recreational. Therapeutic applications explore-aq nalluniluku. Jessica-aq question-aq blind spot expose mission-aq.

Bentley-aq save determination-aq, Colin-aq CBD golden paste create learn — specialized cannabinoid formula pets-aq. Cure-aanqigciit, lifeline-aq. Hope-aq deliver something veterinary medicine impossible: Bentley-aq get up, walk over Colin-aq ball-aq bring. Paralyzed euthanasia face-aq ball fetch. Placebo-aanqigciit — dogs placebo-aq respond nalluniluku. Cannabinoid medicine-aq pharmaceuticals could not do.

Bentley-aq ten years live, age twenty-aami naturally pass. Years-aani Colin-aq specialized formulas every age-related condition-aq develop. Neurodegeneration-aq CBG-aq neuroprotective properties-llu THCa-aq PPARγ agonism brain cell protection-aq understand. Dementia-aq CBC-aq neurogenesis role-aq. Glaucoma-aq THC-aq CB1 agonism intraocular pressure reduction-aq. Crippling arthritis-aq multi-pathway anti-inflammatory approaches CBD, CBG, THCa, beta-caryophyllene simultaneously use-aq.

Single cannabinoids enough nalluniluku. Bentley-aq evolving conditions-aq multi-cannabinoid synergy require. Minor cannabinoids CBG, CBN, CBC-aq critical. Pharmaceutical precision matter-aq — Bentley-aq life formula accuracy depend, guesswork nalluniluku.

Bentley-aq journey-aq Colin-aq cannabis high-aq beyond entry. Real solutions create mission-aq pain sufferring-aq alleviate, pets-aq people-lu. Bentley-aq story-aq OilWell Cannabis foundation-aq drive, quality, innovation, compassionate care-aq commitment-aq.

Colin Personal Battle: PTSD-llu Benzo Addiction

Colin-aq pharmaceutical dependence personally know-aq. PTSD-llu benzodiazepine addiction-aq struggle. Xanax free break decision-aq cold turkey — notoriously difficult dangerous — cannabinoid knowledge-aq Bentley-aq alive keep develop-aq use.

Peace Gummies formula-aq midnight experiments-aq create while benzo withdrawal-aq fight. Vape form-aq personally insomnia-llu severe PTSD-aq manage. Theoretical knowledge-aanqigciit. Colin-aq RSO patients-aq live: relief desperation, pharmaceuticals fail, cannabinoids work when pills do not discovery.

Houston-mek Bethel Census Area-mun: Reach-put

Today, OilWell Cannabis-aq Montrose, Houston, Texas (810 Richmond Avenue)-aami operate. 2019-aami operating, approximately one million dollars annual revenue, near-5.0 Google rating, Texas DSHS licensed. Products-aq mass-produced-aanqigciit — personal touch carefully craft, packaging artwork-llu formulations-llu. Artwork, formulations, packaging-aq Houston-aami in-house create, own recipes ideas use-aq.

Reach-aq Texas-aq beyond. Customers-aq United States across-llu internationally-llu — remote Alaska-lu serve. Bethel Census Area-aami, shipping address-aanqigciit. Community-aq respect integrity Houston neighbors show same serve.

OilWell RSO Philosophy: Four Core Principles

OilWell-aq RSO-aq traditional Rick Simpson Oil-aanqigciit. Formulated, multi-cannabinoid product-aq RSO tradition-aq informed but five evidence-motivated ways-aaneng deliberately different problems Simpson-aq original vision solve.

1. Accessibility Over Gatekeeping

Medical card required nalluniluku. Twenty-one or older anyone purchase. Nationwide United States across ship, international customers-aq local legality verify. Simpson-aq medicine-aq everyone accessible believe-aq; product distribution model-aq legal accessible build.

Bethel Census Area-aami yuut revolutionary. Anchorage-aam medical cannabis certification-aq fly nalluniluku. Alaska-aq complex medical marijuana program-aq navigate nalluniluku. Twenty-one-aami order. Bethel, Kwethluk, Napakiak-aami Census Area-aam any village-aami door-aq ship.

2. Patient-Controlled Potency

THCa-aq acidic, non-psychoactive form-aani sell. Raw non-psychoactive benefits use or delta-9 THC-llu decarboxylate full psychoactive potency-llu decide. Simpson-aq patients medicine-aq control believe-aq; chemistry-aq product-aq hands-aq control engineer.

Bethel Census Area-aami places most matters. Long winter months-aami daylight scarce, seasonal affective disorder real, psychoactive option want-aq. Fishing season-aami boats equipment-llu operate safely need, non-psychoactive option need. One product both needs serve.

3. Open-Source Formulas

Complete formulas publicly publish — every cannabinoid, every milligram amount, every percentage — product afford nalluniluku ingredients source own version make can. Simpson-aq oil free give teach make; ethos modern cannabinoid marketplace-aq adapted.

Region-aani cost of living 50% national average above, shipping costs extreme. RSO Sublingual Oil-aq $129.99. Budget beyond-aani, exact formula (16,590 mg total cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg) see individual distillates source.

4. Evidence-Informed, Not Evidence-Overstating

Scientific evidence section-aq document-aq commit honest education science actually says. Simpson-aq peer-reviewed literature or clinical trial data access operate nalluniluku; access-aq have well-supported, emerging, overstated distinguish use.

Remote region-aani medical oversight limited health decisions-aq make, facts need, hype nalluniluku. Man’a provide.

Farm Bill Compliance and THCa Legal Framework

2018 Farm Bill-aq hemp-llu hemp-derived products-aq legalize less than 0.3% delta-9 THC dry weight federal level. Legal framework-aq product design foundation.

RSO Sublingual Oil-aq entire 30 mL bottle-aani 90 mg delta-9 THC contain — 3 mg per mL — 0.3% threshold well under. Cannabinoids-aq hemp-derived. Alaska-aami-llu legal.

THCa game-changer-aq. THCa (tetrahydrocannabinolic acid) acidic, non-psychoactive THC precursor. Itself delta-9 THC-aanqigciit. Legally significant: THCa-aq Farm Bill compliant point of sale-aani delta-9 THC convert nalluniluku.

Practical significance substantial. Home-aani THCa delta-9 THC-llu decarboxylate can oil-aq 260°F (125°C) 45-60 minutes oven-safe glass container-aani. 1,500 mg THCa approximately 1,315 mg delta-9 THC convert. Existing 90 mg delta-9 THC-llu combine approximately 1,405 mg total delta-9 THC produce — traditional illegal RSO psychoactive potency comparable, discretion entirely purchase after.

Alaska residents-aani: Alaska law-aq Farm Bill definition follow. Products-aq purchase, possess, use legal Alaska state across, Bethel Census Area-lu. Alaska-aami ship full documentation, Certificates of Analysis, receipts.

Legal notice important: THCa-aq heated delta-9 THC convert. Local laws comply understand responsible. OilWell full documentation ship. International customers customs legal risk all accept.

Formulas-put Traditional RSO-mek Diverge: Evidence-Motivated Five Ways

1. Multi-Cannabinoid Approach

Traditional RSO-aq single strain maker grew or sourced rely. Formulas-aq seven cannabinoids intentionally include because entourage-effect literature cannabinoid diversity potential benefit suggest, robust clinical proof whole-formula synergy limited remain [20][29].

Bethel Census Area-aami yuut multiple conditions deal — commercial fishing injuries chronic pain, traumatic experiences PTSD, seasonal light changes sleep disruption — single cannabinoid often enough nalluniluku. Multi-cannabinoid approach multiple pathways simultaneously address.

2. Terpene Preservation and Addition

Traditional RSO-aq solvent-llu heat destruction-aani essentially terpene content none. Live terpenes 5% specific seven-terpene profile include: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene. Terpene bioactivity plausible preclinical level support, human clinical confirmation developing remain [20][21][23][24][25][26][27][28][29].

Bethel Census Area-aami subarctic environment-aani seasonal affective disorder many residents affect, limonene-llu linalool-llu mood-modulating potential terpenes particularly relevant.

3. THCa Separate Ingredient

Traditional RSO-aq everything fully decarboxylate, all THCa delta-9 THC convert. Sublingual formula-aq 1,500 mg distinct ingredient-aaneng THCa include, acidic precursor preserve because THCa literature non-psychoactive bioactivity potentially relevant suggest THCa THC convert lost [12].

Control give. Fishing season-aami raw use equipment operate safely. Dark winter months-aami psychoactive relief prefer decarboxylate.

4. Reduced Delta-9 THC Dominance

Traditional RSO-aq 60-90% delta-9 THC. Formula-aq delta-9 THC 90 mg only use while remaining cannabinoid content CBD, CBG, delta-8 THC, CBN, CBC-lu distribute. Broader cannabinoid research landscape reflect rather than single-compound dominance model.

Bethel Census Area-aami fishing industry, healthcare, education employment drug testing concern residents-aani reduced delta-9 content significant. Raw formula psychoactive effects cause nalluniluku, non-psychoactive cannabinoids-llu positive drug tests trigger may. Honest: raw THCa non-psychoactive stay, delta-8-llu activated THCa tests trigger. Informed be.

5. Product Format Innovation

Simpson-aq one format only envision: syringe-aani oral oil. Both 30 mL sublingual oil-llu 1-gram vape cartridge-llu offer, format-specific formulations acknowledge different delivery routes different pharmacokinetic profiles have [14].

Bethel Census Area-aami weather extreme, outdoor activities central. Options matter. Sublingual oil long days river-aani sustained relief work. Vape cartridge remote location-aani breakthrough pain or panic attacks-aani fast relief.

Solvent-Free Production: Alaska-aani Why Matters

Traditional RSO production-aq naphtha or isopropyl alcohol use — food-grade-aanqigciit. Naphtha petroleum mixture benzene carcinogens-llu contain. Incomplete solvent purging-aq toxic residues leave.

RSO-aq traditional sense extraction product-aanqigciit. Individual cannabinoid distillates-llu isolates-aq specific ratios controlled production environment-aani combine formulated blend. Naphtha nalluniluku. Isopropyl alcohol nalluniluku. Butane nalluniluku. Finished product-aani extraction solvents present nalluniluku.

Carrier base-aani organic MCT oil (medium-chain triglycerides) use. MCT oil food-grade lipid carrier cannabinoid absorption sublingual tissue-aani facilitate, neutral taste profile provide — traditional RSO tar-like consistency-llu solvent-residual odor-aq significant improvement.

Third-party lab testing cannabinoid potency, terpene profile, safety panels pesticides, heavy metals, residual solvents, microbial contaminants-llu cover. Certificates of Analysis (COAs) request-aani available website-aani-llu access.

Bethel Census Area-aami subsistence living teach body-aani put respect. Purity-llu transparency-aq level matter. Contaminated food neighbors-aani send nalluniluku. Contaminated medicine yourself accept nalluniluku.

Decarboxylation Choice: Potency-llu Control-llu

Traditional RSO always fully decarboxylate psychoactive. Choice none. Sublingual formula-aq 1,500 mg THCa acidic non-psychoactive form contain, three distinct usage options create:

Option 1: Raw, No Heat (Non-Psychoactive)

1,500 mg tamarmeng THCa stay — completely non-psychoactive. THCa evidence-aq potential anti-inflammatory activity COX-2 inhibition-aani-llu neuroprotective potential PPARγ agonism-aani [12]. Work, drive, daytime use zero impairment compatible.

Bethel Census Area-aami commercial fishermen, healthcare providers, teachers, heavy equipment operators work residents-aani equipment operate safely anti-inflammatory support get safety compromise job performance nalluniluku.

Option 2: Fully Activated (Home Decarboxylation)

Oil-aq 260°F (125°C) 45-60 minutes oven-safe glass container-aani heat. 1,500 mg THCa approximately 1,315 mg delta-9 THC convert. Existing 90 mg delta-9 THC-llu combine approximately 1,405 mg total delta-9 THC yield — traditional illegal RSO psychoactive potency comparable, discretion entirely purchase after.

Entire bottle decarboxylate or controlled portion second container-aani transfer, remainder raw preserve. Bethel Census Area-aani seasonal mental health-llu chronic pain severity variations require different approaches flexibility valuable.

Option 3: Vape Cartridge (Auto-Decarboxylation)

RSO Vape Cartridge-aq 400-450°F vaporize, THCa instantly delta-9 THC convert each inhalation-aani. Every puff freshly decarboxylated cannabinoids deliver. Fastest-onset RSO delivery method — 1-2 minutes.

Conversion chemistry: 1 mg THCa = 0.877 mg delta-9 THC decarboxylation after, CO₂ molecule loss reflect.

Bethel Census Area-mun Delivery: How Works

Alaska-aami ship. Remote areas-aami ship. “Overnight delivery” Yukon-Kuskokwim Delta-aani existence nalluniluku understand.

Alaska-aami nationwide shipping:

• USPS Priority Mail (3-5 business days Bethel-aam)
• FedEx-llu UPS Ground (5-7 business days)
• Cannabis branding visible nalluniluku discreet packaging
• All orders tracking provide
• Extreme Alaskan temperatures-aani temperature-stable packaging
• Signature-required option available

International shipping: Multiple countries multiple continents-aami ship. THCa legal framework possible: product-aq 0.3% delta-9 THC less contain point of sale-aani 2018 Farm Bill hemp-derived product definition meet, compatible hemp laws jurisdictions-aami shippable.

Bethel Census Area-aami residents-aani: Rural Alaska shipping costs extreme understand. Inflate nalluniluku. Actual carrier rates charge. $200 over orders-aani discounted shipping offer. Specific location-aani options discuss (832) 416-2816 or [email protected] contact.

All packages full documentation, Certificates of Analysis (COAs), customs purposes receipts include. Jurisdiction-aani legality verify customs legal risk all accept responsible.

Two Product Formats: Life-put Works Choose

RSO Sublingual Oil — $129.99

• 30 mL bottle (serving size depend 40-60 doses)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper precise dosing 0.1 mL increments-aani
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Bioavailability: 13-19%

Bethel Census Area-aani why matters: Long duration long winter nights-aani active summer days-aani sustained relief perfect. Precise dosing region-aani medical help hours away may careful titrate essential.

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900+ mg total cannabinoids
• Six cannabinoids (sublingual same ratio, delta-9 separate listing none because vaping temperature-aani THCa auto-decarbs)
• Live terpenes 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery)
• Duration: 2-4 hours
• Bioavailability: 10-35%

Bethel Census Area-aani why matters: Fishing trip-aani breakthrough pain-aani remote location-aani panic attack-aani deal when hours medical help 1-2 minute relief life-changing. Compact size pocket or dry bag-aani easily fit.

Each Format When Use

Use case	Recommended format	Bethel Census Area-aani rationale
Fast relief (acute pain, nausea, panic)	Vape	Hours medical help may 1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	Long nights active days cover 4-6 hour duration
Maximum bioavailability	Sublingual	Limited supply maximize 13-19% absorption
Portability and discretion	Vape	Villages or tundra-aani travel compact
Precise dosing control	Sublingual	Remote settings essential graduated dropper
Daytime non-psychoactive use	Sublingual (raw)	Boats, equipment, vehicles operate safely
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Seasonal affective disorder, insomnia relief

Bethel Census Area-aani Condition-Specific Usage Context

Important disclaimer: Contexts-aq cited cannabinoid research-aq formulation rationale-aq informed. Medical prescriptions-aanqigciit, FDA-approved treatment protocols-aanqigciit, professional medical care substitute-aanqigciit. Products-aq Food and Drug Administration evaluate nalluniluku, diagnose, treat, cure, or prevent any disease intended nalluniluku. Cannabinoid products use-aani qualified healthcare provider always consult especially medical condition, medications take-aq, pregnant or nursing, health concerns any. Psychoactive cannabinoids influence-aani vehicles or machinery operate nalluniluku.

Chemotherapy-Related Nausea and Appetite Support

Bethel Census Area-aami residents Anchorage or Seattle-aani cancer treatment travel-aq:

• Pre-chemo: 0.5-1.0 mL sublingual treatment-aani approximately 1 hour before
• Acute breakthrough nausea: immediate relief (1-2 minute onset) 2-3 vape puffs
• Post-chemo: every 6 hours as needed 0.5 mL sublingual
• Treatment-aani sleep support: bed before 1.0-2.0 mL sublingual (25-50 mg CBN deliver)

Evidence: delta-8 THC antiemetic [9], delta-9 THC nausea vomiting evidence [1][13], CBD anxiolytic buffering [3]

Reality check: Many Bethel Census Area-aami residents cancer treatment travel. Travel-aani nausea management portable legal option valuable. Taugaq medical care complement; oncologist prescribe antiemetics replace nalluniluku.

Chronic Pain (Fishing Injuries, Arthritis, Neuropathy)

Chronic pain-aq Bethel Census Area-aami commercial fishing, construction, subsistence activities physically demanding work-aani widespread:

• Daytime: 0.3-0.5 mL raw sublingual — impairment akeqcaayuunateng anti-inflammatory support
• Nighttime: 0.5-1.0 mL decarboxylated sublingual — pain relief CBN sleep support combine
• Breakthrough pain: active work-aani rapid onset as needed vape

Evidence: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Alaska-specific consideration: Cold joint pain amplify. Anti-inflammatory multi-pathway approach (CBD, CBG, THCa, caryophyllene) Alaska markets common single-cannabinoid CBD products-aani more effective may.

Long Winter Nights Sleep Support

Seasonal affective disorder-llu circadian rhythms disrupted Bethel Census Area-aami many affect:

• Bed before: 1.0-2.0 mL sublingual
• 2.0 mL-aami 50 mg CBN deliver — 2024 sleep literature investigate dosage level
• 1.0 mL-aami 25 mg CBN deliver — published research reduce sleep disturbance 20 mg threshold above

Evidence: CBN sleep evidence [16][17], cannabis sleep review literature

Important caveat: CBN-aq sleep evidence marketing suggest weaker [16][17]. Some users benefit report, taugaq clinically proven nalluniluku. Expectations manage accordingly.

Isolated Communities Anxiety and Stress

Rural Alaska life beautiful, isolating stressful-llu:

• Daytime functional relief: 0.3 mL raw sublingual — anxiety pathways CBD-llu CBG-llu address impairment akeqcaayuunateng
• Nighttime: 1.0 mL sublingual — CBN sleep architecture include full profile

Evidence: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

Community mental health context: Bethel Census Area-aami suicide, substance abuse, mental health access challenges significant face. Product-aq anxiety symptoms manage may, professional mental health care substitute-aanqigciit. Local resources Yukon-Kuskokwim Health Corporation Behavioral Health Department or Alaska Careline (1-877-266-4357) serious mental health concerns-aani reach out.

General Titration Principle: Start Low, Go Slow

0.25-0.5 mL sublingual start 2-3 hours effects assess increase-aani before. Individual responses body weight, metabolism, tolerance, concurrent medications, other factors-aani vary.

Remote setting caution: Bethel Census Area-aani emergency medical services delayed may, conservative dosing especially important. More always take can; less take can’t once system-aani.

Competitive Comparison: OilWell Alone Stand

OilWell RSO vs. Traditional RSO (Alaska-aami Find Might)

Dimension	Traditional RSO	OilWell RSO
Cannabinoid profile	THC-dominant, uncontrolled	7 cannabinoids specific ratios-aani
Terpenes	Heat-aani destroyed	Live terpenes 5%
Standardization	None — every batch different	Lab-tested specific mg/mL targets-aani
Safety testing	Not performed	Full panel testing (pesticides, heavy metals, solvents, microbes)
Solvents	Naphtha/isopropyl risk	No solvents — pure distillates formulated
Legal status	Alaska-aami illegal (medical-aanqigciit)	Farm Bill compliant, legal ship
Access	Black market only	Bethel Census Area-aami direct ship
Potency control	Always psychoactive	Activation control

OilWell RSO vs. Alaska Medical Marijuana Program

Alaska-aq medical marijuana program-aq, access limited:

• Physician certification state registration require
• Limited dispensary locations (Bethel Census Area-aani none)
• Anchorage or urban centers-aani travel must
• Higher delta-9 THC content (some desirable but others problematic)

OilWell offer:

• Medical card required nalluniluku (21+)
• Bethel Census Area-aami door-aq direct ship
• Lower delta-9 THC baseline patient-controlled activation-llu
• Alaska medical dispensaries-aani not available multi-cannabinoid profile

Important: Alaska-aq medical marijuana program-aani enrolled already-aani, products-aq regimen complement can but physician consult nalluniluku prescribed medications replace nalluniluku.

Each Cannabinoid Evidence: Science Says

CBD: Most Studied Cannabinoid

Best supported evidence: Purified CBD rare epilepsies-aani seize disorders-aani strongest human evidence [1][2]. Institutional literature acknowledge clearest major indication.

Anxiety: 2024 systematic review meta-analysis 316 participants eight studies cover statistically significant anxiolytic signal report, but authors clinical sample limited more trials need stress [3].

Pain: 2024 systematic review clinical preclinical CBD monotherapy studies conclude pain literature promising but heterogeneous, trial quality broad analgesic claims limit [4].

Sleep: 2023 insomnia review literature methodologically weak find, many studies nonvalidated subjective measures rely, objective sleep assessments few [5].

Safety concerns: 2023 systematic review meta-analysis liver enzyme elevation real signal find, possible drug-induced liver injury especially concentrated oral products polypharmacy settings relevant [6]. NCCIH diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, drug-drug interactions-llu flag [1].

Bottom line: CBD most evidence-developed nonintoxicating cannabinoid, taugaq strong evidence specific indications rather than broad wellness claims concentrate [1]-[6].

CBG: “Mother Cannabinoid”

Evidence profile: Mostly review preclinical; human evidence sparse remain [7][8].

Pharmacology: CBG major cannabinoids biosynthetic precursor, THC-llu CBD-lu pharmacologically distinct appear. Cannabinoid receptors, alpha-2 adrenoceptors, 5-HT1A-related signaling interact — mechanistically interesting but clinically establish nalluniluku [7].

Potential areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity possible relevance discuss reviews, primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions [7][8].

Caution: 2021 pharmacology review explicitly state CBG commercial sell already evidence base thin, claims frequently science outrun [7].

Bottom line: CBG promising minor cannabinoid limited clinical validation, proven therapeutic cannabinoid nalluniluku [7][8].

Delta-8 THC: “Weed Lite” Not

Evidence profile: Pharmacologically relevant, psychoactive, delta-9 THC much less clinically characterize [9]-[11].

Comparative pharmacology: 2022 review conclude delta-8-llu delta-9 THC broadly similar pharmacokinetic pharmacodynamic behavior. Delta-8 partial CB1 agonist animal human cannabimimetic activity, taugaq delta-9 weaker CB1 affinity less potent likely [9].

Public health literature: 2023 scoping review delta-8 evidence base animal studies, product chemistry, use reports, public-health concerns dominate rather than strong human trials. Adverse consequences reports exist, regulatory product-quality concerns emphasize [10].

Manufacturing context: Commercial delta-8 interest naturally scarce plant levels relative greater stability easier synthesis tie, product-byproduct lab-testing questions raise [11].

Bottom line: Delta-8 THC psychoactive THC analogue treat, real pharmacologic activity, incomplete human safety characterization, manufacturing-quality uncertainty many consumers realize [9]-[11].

THCa: Legal Distinction Everything Changes

Evidence profile: Chemically formulation-wise important, direct human therapeutic evidence low [12].

What it is: THCa THC acidic precursor, raw plant material-aani THC-related content large share represent. Heating-aani THC decarboxylate, storage processing-aani time change can [12].

Psychoactivity: THCa itself THC associated psychoactive effects produce nalluniluku, taugaq distinction acidic form stay substantially decarboxylate nalluniluku only hold [12].

Research status: In vitro rodent literature anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities suggest, taugaq established human outcomes equivalent nalluniluku [12].

Bottom line: THCa highly relevant precursor molecule best understand, interpretation heavily route, temperature, processing, storage depend. THCa claim possible THC conversion account must [12].

Delta-9 THC: Most Studied Psychoactive Cannabinoid

Evidence profile: Listed psychoactive cannabinoids strongest human evidence, clearest adverse-effect burden [1][13]-[15].

Best institutional support: NCCIH THC-containing cannabinoid medicines chemotherapy-related nausea vomiting, HIV/AIDS appetite/weight loss, some multiple sclerosis pain outcomes relevant identify, many other uses uncertain stress [1].

Pain evidence: 2022 systematic review high THC content or comparable THC:CBD ratios products short-term pain benefit provide but dizziness, sedation, nausea, adverse events treatment discontinuation increase find [13].

Pharmacokinetics: Inhaled THC seconds minutes-aani effects produce, 15-30 minutes peak, few hours taper. Oral THC later onset, later peak, longer duration [14].

Mental health risk: 2025 high-concentration THC products systematic review psychosis/schizophrenia outcomes consistent unfavorable associations find, cannabis use disorder, nontherapeutic settings anxiety depression concerning signals [15].

Broader safety: High doses-aani anxiety or panic, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape lung-injury concerns include [1][14][15].

Bottom line: Delta-9 THC some settings legitimate therapeutic relevance, taugaq clearest intoxication, psychiatric, dose-related safety liabilities this document-aani [1][13]-[15].

CBN: “Sleep Cannabinoid” Weak Evidence

Evidence profile: Weak human evidence; marketing data ahead move [12][16][17].

Reputation: Sleep sedation. Reputation widespread, taugaq clinical support marketing suggest far thinner [16][17].

Best sleep claim review: 2021 CBN sleep narrative review 99 human-study abstracts screen, eight full-text articles review, validated sleep questionnaires or formal polysomnography use clinical trials none find strong sleep-promoting claims substantiate [16].

Broader sleep literature: 2024 updated review overall cannabinoid sleep research real-world use scale still match nalluniluku, better-designed adequately powered trials need substantial remain conclude [17].

Bottom line: CBN cultural reputation current clinical evidence stronger clearest example [16][17].

CBC: Emerging Minor Cannabinoid

Evidence profile: Emerging, intriguing, overwhelmingly preclinical review-based [18][19].

Pharmacology: 2024 focused review CBS distinct pharmacodynamics, pharmacokinetics, receptor behavior argue, antinociceptive, antibacterial, anti-seizure areas especially interesting research targets highlight [18].

Older literature: Anti-inflammatory effects, gut hypermobility reduce, modest rodent analgesic activity, neurobiological antiproliferative relevance possible, taugaq signals patient-facing claims strong evidence nalluniluku [19].

Safety caveat: 2024 CBC review explicitly note over-the-counter CBC products already sell despite clinical efficacy or safety establish little evidence [18].

Bottom line: CBC scientifically credible minor cannabinoids deserve more research category belong, already-validated clinical actives category nalluniluku [18][19].

Terpenes: Aromatic Dimension

Terpene claims cannabinoid claims stricter interpretation need. Much literature isolated compounds, essential oils, non-cannabis plants, preclinical models rather than controlled cannabis formulation human studies come. 2024 entourage-effect review especially important: terpene bioactivity plausible sometimes compelling, but robust clinically meaningful entourage effects humans-aani proof limited remain [20][29].

Limonene: Citrus Brightness

Evidence profile: Largely review preclinical, useful safety literature [20]-[22].

Potential activity: 2021 review limonene multifunctional monoterpenes antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possible activities describe, but claims overwhelming share nonhuman or non-cannabis literature come [21].

Safety note: Limonene oxidation products, especially hydroperoxides, patch-testing literature clinically relevant contact allergens [22].

Bottom line: Limonene biologically active widely discuss, taugaq cannabis-specific therapeutic claims human-aani directly support unless conservative stay [20]-[22].

Myrcene: Earthy Depth

Evidence profile: Mostly preclinical, human evidence very limited [20][23].

Research summary: 2021 myrcene review anxiolytic, antioxidant, anti-inflammatory, analgesic properties describe, possible mechanisms discuss but human studies lacking explicitly state [23].

Interpretation caution: Myrcene proven sedating terpene couch-lock or sleep effects explain often invoke, human evidence currently support stronger claim [20][23].

Bottom line: Myrcene plausible bioactive terpene, taugaq compound-specific mood, pain, sedation claims human proof definitive ahead far [23].

Caryophyllene: CB2 Agonist

Evidence profile: Cannabinoid-system relevance direct because most mechanistically interesting terpenes, but mostly preclinical [24].

Why it stands out: 2021 focused review beta-caryophyllene selective CB2 receptor agonist describe, unusual and cannabis terpenes pharmacologic rather than purely aromatic terms discuss especially relevant make [24].

Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective related actions review literature repeatedly discuss, taugaq human clinical confirmation limited remain [24].

Bottom line: Beta-caryophyllene cannabinoid-system significance terpene arguably strongest candidate, taugaq clinically proven nalluniluku outcomes commonly attribute describe should [24].

Pinene: Forest Fresh

Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25].

Brain-health framing: 2021 pinene linalool brain health terpene-based medicines review antioxidant, anti-inflammatory, neuroprotective signals find future study justify but evidence mostly preclinical well-designed clinical trials lacking emphasize [25].

Interpretation caution: Pinene memory improve, attention sharpen, THC-related cognitive effects counterbalance reliably claims interesting hypotheses rather than settled clinical facts remain [20][25].

Bottom line: Pinene scientific attention deserve, taugaq strong cognition-related claims exploratory present should [25].

Linalool: Floral Calm

Evidence profile: Pinene similar: substantial preclinical interest, limited direct clinical confirmation

ENGLISH

Rick Simpson Oil (RSO) in Bethel Census Area, Alaska: The Complete Guide by OilWell Cannabis

Living in Bethel Census Area means understanding what it means to be remote. To have one hospital serving a region the size of Oregon. To face winter nights that stretch for twenty hours and temperatures that freeze medicine in transit. When you’re in a place where medevac flights are routine and specialist care is a plane ride away, you learn to take health into your own hands. That’s why OilWell Cannabis created something different: a modern, legal, multi-cannabinoid RSO that honors Rick Simpson’s original vision while solving the problems that made traditional RSO unsafe and unreliable.

This isn’t hype. This is the most comprehensive, evidence-based RSO education available anywhere — written specifically for the people of Bethel Census Area, from the tundra villages of the lower Kuskokwim to the fishing communities along the Yukon River. Whether you’re in Bethel city, Kwethluk, Napakiak, or one of the thirty-four remote villages that make up our Census Area, you deserve honest answers about what RSO is, what it can and cannot do, and how to access it legally and safely.

Who Was Rick Simpson? Understanding the Man Behind the Oil

Rick Simpson wasn’t a doctor. He wasn’t a scientist. He was a power engineer from Nova Scotia — a blue-collar tradesman whose life changed in 1997 when he fell from scaffolding at a hospital in Moncton, Canada. The head injury left him with persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t fix. The medications either didn’t work or made things worse. When he asked his doctor about cannabis, the doctor refused to discuss it .

Sound familiar? In Bethel Census Area, we’ve all seen friends and family go through similar cycles: workplace injuries from fishing, construction, or transportation; chronic pain that doesn’t respond to pills; doctors who dismiss cannabis as an option. The frustration of being told “there’s nothing more we can do” is universal, whether you’re in downtown Bethel or a village accessible only by plane.

Simpson discovered a 1974 NIH-funded study from the Medical College of Virginia that showed THC could slow or shrink tumors in mice. That study — intended to prove harm — became his inspiration, even though its findings were never replicated in controlled human trials . In 2003, Simpson claimed that applying concentrated cannabis oil to three bumps on his arm (diagnosed as basal cell carcinoma) made them disappear in four days. No biopsy confirmation. No independent medical verification. No peer-reviewed documentation. But that personal testimony became the origin story of Rick Simpson Oil .

Important context: Simpson’s account is personal testimony, not medical evidence. It’s historically significant as the catalyst for a global movement, but it cannot be evaluated as clinical proof. For Bethel Census Area residents facing serious health decisions, understanding this distinction is crucial.

The Crusade: How RSO Became a Global Movement

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil. He gave it away for free to cancer patients and others in his community in Maccan, Nova Scotia. He claimed to help people with cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more — conditions that affect people across Bethel Census Area every day .

In 2005, the documentary Run From The Cure made Simpson’s story global. It was distributed freely online and became foundational in cannabis communities worldwide. For many people in Bethel Census Area, this documentary was their first introduction to the concept of concentrated cannabis oil as medicine .

But Simpson’s advocacy brought legal conflict. The Royal Canadian Mounted Police raided his property in 2005 and again in 2009. He faced charges for cultivation, possession, and trafficking. Eventually, he left Canada for Europe, continuing his advocacy from Croatia and the Netherlands . He published Phoenix Tears in 2012 and maintained phoenixtears.ca as his platform .

Throughout his public career, Simpson maintained that RSO could cure cancer and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge. He framed his work as fighting institutional corruption .

Important context: Simpson’s conspiratorial worldview reflects early cannabis movement distrust of institutions. In Bethel Census Area, where many residents have experienced healthcare gaps, long wait times, or dismissive medical encounters, that skepticism resonates. But at OilWell, we believe in addressing concerns with evidence, not conspiracy theories.

The Traditional RSO Protocol: Simpson’s 60-Gram, 90-Day Regimen

Simpson’s core treatment recommendation was consuming 60 grams of concentrated cannabis oil over approximately 90 days. Here’s exactly what he prescribed :

Week 1: Start with a dose the size of half a grain of rice (about 10-15 mg) taken three times daily. Total daily intake: 30-45 mg.

Weeks 2-5: Double the dose approximately every four days to slowly build tolerance to THC’s psychoactive effects. The goal is to reach 1 gram (1,000 mg) of oil per day, divided into three doses of roughly 333 mg each.

Weeks 5-12: Maintain 1 gram per day until all 60 grams are consumed.

Administration methods: Oral (primary), topical for skin cancers, and inhalation for immediate symptom relief but not as primary treatment.

Important context for evaluating this protocol:

• No controlled trial validation. Not one randomized controlled trial, cohort study, or well-documented case series supports this protocol .
• It assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency — actual THC content varied widely depending on starting material and extraction technique.
• Very high THC exposure. At peak dosing, traditional RSO delivered approximately 600-900 mg of delta-9 THC per day. The FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5-20 mg per day. This is a 30-360x higher dose than anything studied in controlled clinical settings.
• Real risks at these doses. Consuming 600-900 mg of THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
• Oncology context. Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as primary treatment — potentially instead of proven therapies — introduces harm that extends beyond the oil itself.

For Bethel Census Area residents, this protocol is particularly concerning. In a region where medical oversight is limited and emergency services may be hours away, attempting to consume 600-900 mg of THC daily without medical supervision is dangerous. This is why OilWell’s approach is fundamentally different.

What Traditional RSO Actually Was

Traditional RSO was defined by Simpson’s method, not lab specifications:

Source material: Single high-THC indica strains, unstandardized, varying by availability and growing season.

Extraction solvent: Naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol — neither food-grade. Naphtha may contain benzene, toluene, and other carcinogens. Incomplete solvent purging leaves toxic residues [1].

Process: Cannabis soaked in solvent, filtered, evaporated in a rice cooker at temperatures high enough to destroy terpenes and fully decarboxylate THCa into THC.

Appearance: Nearly black, tar-like, thick oil with strong cannabis odor and possible solvent-residual smell.

Cannabinoid profile: THC-dominant (60-90% estimated), fully decarboxylated, with minor cannabinoids at natural ratios — uncontrolled, unmeasured, never lab-verified.

Terpene content: Minimal to none. The solvent and heat process destroyed volatile terpenes, leaving a cannabinoid-only product despite being derived from a terpene-rich plant.

Standardization and testing: None. Every batch was different. No Certificate of Analysis, no cannabinoid quantification, no contaminant screening.

Residual solvent risk: This is one of the most significant safety concerns. Traditional RSO production left potentially harmful solvent residues in the finished oil [1].

In Bethel Census Area, where many people practice subsistence living and have experience with traditional plant medicine, the idea of making your own medicine resonates. But traditional RSO’s solvent safety issues are especially relevant here. In a remote region with limited access to analytical chemistry equipment, verifying solvent removal is impossible. This is why modern extraction methods using food-grade ethanol or CO₂ are critical improvements.

The Evidence: What Science Actually Shows

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious biomedical research area when the world was ignoring it. He helped create the conditions for the legal cannabis industry. The term “RSO” remains the most recognized name for full-spectrum cannabis extract. These contributions are real and historically significant .

What He Overstated

Simpson’s cure claims exceeded the evidence. Encouraging patients to use RSO instead of proven cancer therapies carries genuine harm potential. Delayed or foregone treatment is a documented concern in alternative medicine .

Institutional positions are clear:

• The U.S. National Cancer Institute acknowledges cannabinoid anticancer research in lab and animal models but does not endorse cannabis as a cancer treatment .
• The FDA has not approved any cannabis plant product for cancer. Only purified CBD (Epidiolex) and synthetic THC analogues (dronabinol, nabilone) have specific approvals for other conditions [1].
• Health Canada has never approved RSO for cancer .
• NCCIH identifies strongest evidence for rare epilepsies, chemo nausea, and HIV/AIDS appetite — not cancer cure [1].

For Bethel Census Area residents facing cancer diagnoses, this honesty is crucial. At the Yukon-Kuskokwim Health Corporation or Bethel Regional Health Center, you may hear about integrative approaches. RSO education complements medical care; it does not replace it. Do not delay proven treatment for unproven alternatives.

About OilWell Cannabis: Our Story

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. But Colin’s story begins in McAllen, Texas — right across the river from Reynosa, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts — vibrant culture but limited opportunities outside retail and healthcare. Reynosa is an industrial hub plagued by cartel violence.

Colin’s childhood in McAllen was marked by exposure to both opportunities and dangers. Early on, he learned to hustle, taking on risky work transporting items across the border. Many of his best friends have been killed or are in prison because of those associated dangers. He faced every form of violence imaginable, both in the streets and across the border. By sixteen, he had to leave home for good.

Despite the dangers, Colin didn’t fall into selling harder substances. He focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — defines OilWell’s approach.

Bentley’s Story: Where Everything Began

The company’s origin story begins with a dog named Bentley. Bentley was more than a pet — he was family. When Bentley fell seriously ill, veterinarians delivered the verdict no owner wants: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs. The choice was painful prolonged decline or immediate mercy killing.

Giving up on Bentley wasn’t an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything. A rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — recreational. He’d never explored therapeutic applications. Jessica’s question exposed a blind spot that became a mission.

Determined to save Bentley, Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It wasn’t a cure, but it was a lifeline. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball. From paralyzed and facing euthanasia to fetching his ball. This wasn’t placebo — dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led to multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working simultaneously.

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. Minor cannabinoids like CBG, CBN, and CBC became critical. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into cannabis beyond getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people. Bentley’s story is the foundation of OilWell Cannabis, driving our commitment to quality, innovation, and compassionate care.

Colin’s Personal Battle: PTSD and Benzo Addiction

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — notoriously difficult and dangerous — using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. Colin personally uses the vape form to manage his insomnia and severe PTSD. This isn’t theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

From Houston to Bethel Census Area: Our Reach

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue). We’ve been operating since 2019, generate approximately one million dollars in annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed. Our products aren’t mass-produced — they’re carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only our own recipes and ideas.

But our reach extends far beyond Texas. We serve customers across the United States and internationally — including remote Alaska. When you’re in Bethel Census Area, you’re not just a shipping address to us. You’re part of a community we respect and want to serve with the same integrity we show our Houston neighbors.

The OilWell RSO Philosophy: Four Core Principles

OilWell’s RSO is not traditional Rick Simpson Oil. It’s a formulated, multi-cannabinoid product informed by the RSO tradition but deliberately different in ways that solve problems Simpson’s original vision couldn’t address.

1. Accessibility Over Gatekeeping

No medical card required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally.

For Bethel Census Area residents, this is revolutionary. You don’t need to fly to Anchorage for a medical cannabis certification. You don’t need to navigate Alaska’s complex medical marijuana program. If you’re twenty-one, you can order. We ship directly to your door in Bethel, Kwethluk, Napakiak, or any village in the Census Area.

2. Patient-Controlled Potency

THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their medicine; we engineered a product that puts that control in your hands through chemistry.

This matters in Bethel Census Area more than most places. During the long winter months when daylight is scarce and seasonal affective disorder is real, you might want the psychoactive option. During fishing season when you need to operate boats or equipment safely, you need the non-psychoactive option. One product serves both needs.

3. Open-Source Formulas

We publish our complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for the modern cannabinoid marketplace.

For a region where the cost of living is 50% above the national average and shipping costs are extreme, this matters. Our RSO Sublingual Oil is $129.99. If that’s beyond your budget, you can see the exact formula (16,590 mg total cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg) and source the individual distillates yourself.

4. Evidence-Informed, Not Evidence-Overstating

The scientific evidence section of this document represents our commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

When you’re making health decisions in a remote region with limited medical oversight, you need facts, not hype. That’s what we provide.

Farm Bill Compliance and the THCa Legal Framework

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of our product design.

Our RSO Sublingual Oil contains only 90 mg of delta-9 THC in the entire 30 mL bottle — 3 mg per mL — well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in Alaska.

THCa is the game-changer. THCa (tetrahydrocannabinolic acid) is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance is substantial. You can decarboxylate THCa into delta-9 THC at home by heating our oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 mg of THCa into approximately 1,315 mg of delta-9 THC. Combined with the existing 90 mg of delta-9 THC in the formula, this produces approximately 1,405 mg of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

For Alaska residents: Alaska law follows the Farm Bill definition. Our products are legal to purchase, possess, and use throughout the state, including in Bethel Census Area. We ship to Alaska with full documentation, Certificates of Analysis, and receipts for your records.

Important legal notice: THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with local laws. OilWell ships with full documentation. International customers accept all customs and legal risk.

Why Our Formulas Diverge from Traditional RSO

We deliberately depart from traditional RSO in five evidence-motivated ways:

1. Multi-Cannabinoid Approach

Traditional RSO relied on whatever single strain the maker grew or sourced. Our formulas intentionally include seven cannabinoids because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

For Bethel Census Area residents dealing with multiple conditions — chronic pain from commercial fishing injuries, PTSD from traumatic experiences, sleep disruption from seasonal light changes — a single cannabinoid often isn’t enough. The multi-cannabinoid approach addresses multiple pathways simultaneously.

2. Terpene Preservation and Addition

Traditional RSO had essentially no terpene content due to solvent and heat destruction. We include live terpenes at 5% with a specific seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation remains developing [20][21][23][24][25][26][27][28][29].

In the subarctic environment of Bethel Census Area, where seasonal affective disorder affects many residents, the mood-modulating potential of terpenes like limonene and linalool may be particularly relevant.

3. THCa as a Separate Ingredient

Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

This gives you control. Use it raw during the fishing season when you need to operate equipment safely. Decarboxylate it during the dark winter months when psychoactive relief might be preferred.

4. Reduced Delta-9 THC Dominance

Traditional RSO was 60-90% delta-9 THC. Our formula uses delta-9 THC at only 90 mg while distributing the remaining cannabinoid content across CBD, CBG, delta-8 THC, CBN, and CBC. This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

For Bethel Census Area residents concerned about drug testing for employment in the fishing industry, healthcare, or education, this reduced delta-9 content is significant. While our raw formula won’t cause psychoactive effects, even non-psychoactive cannabinoids may trigger positive drug tests. We are honest about this: THCa stays non-psychoactive when raw, but delta-8 and activated THCa will trigger tests. Be informed.

5. Product Format Innovation

Simpson envisioned only one format: oral oil from a syringe. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulations acknowledging that different delivery routes have different pharmacokinetic profiles [14].

In Bethel Census Area, where weather can be extreme and outdoor activities are central to life, having options matters. The sublingual oil works for sustained relief during long days on the river. The vape cartridge provides fast relief for acute breakthrough pain or panic attacks.

Solvent-Free Production: Why It Matters for Alaska

Traditional RSO production used naphtha or isopropyl alcohol — neither food-grade. Naphtha is a petroleum mixture that may contain benzene and other carcinogens. Incomplete solvent purging leaves toxic residues.

Our RSO is not an extraction product in the traditional sense. It’s a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

We use organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile — a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

In Bethel Census Area, where subsistence living teaches you to respect what you put in your body, this level of purity and transparency matters. You can’t send contaminated food to your neighbors. You shouldn’t accept contaminated medicine for yourself.

The Decarboxylation Choice: Your Potency, Your Control

Traditional RSO was always fully decarboxylated and psychoactive. You had no choice. Our sublingual formula contains 1,500 mg of THCa in its acidic, non-psychoactive form, creating three distinct usage options:

Option 1: Raw, No Heat (Non-Psychoactive)

All 1,500 mg stays as THCa — completely non-psychoactive. The THCa evidence shows potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving, and daytime use with zero impairment.

For Bethel Census Area residents working as commercial fishermen, healthcare providers, teachers, or heavy equipment operators, this means you can get anti-inflammatory support without compromising safety or job performance.

Option 2: Fully Activated (Home Decarboxylation)

Heat the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 mg of THCa into approximately 1,315 mg of delta-9 THC. Combined with the existing 90 mg of delta-9 THC, this yields approximately 1,405 mg of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion.

You can decarboxylate the entire bottle or transfer a controlled portion into a second container, preserving the remainder raw. This flexibility is especially valuable in Bethel Census Area, where seasonal variations in mental health and chronic pain severity require different approaches.

Option 3: Vape Cartridge (Auto-Decarboxylation)

Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available — 1-2 minutes.

Conversion chemistry: 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule.

Delivery to Bethel Census Area: How It Works

We ship to Alaska. We ship to remote areas. We understand that “overnight delivery” doesn’t exist in the Yukon-Kuskokwim Delta.

Nationwide shipping to Alaska:

• USPS Priority Mail (3-5 business days to Bethel)
• FedEx and UPS Ground (5-7 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for extreme Alaskan temperatures
• Signature-required option available

International shipping: We ship to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3% delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

For Bethel Census Area residents: We understand shipping costs to rural Alaska are extreme. We don’t inflate them. We charge actual carrier rates. For orders over $200, we offer discounted shipping. Contact us at (832) 416-2816 or [email protected] to discuss options for your specific location.

All packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes. You are responsible for verifying legality in your jurisdiction and accepting all customs and legal risk.

Two Product Formats: Choose What Works for Your Life

RSO Sublingual Oil — $129.99

• 30 mL bottle (approximately 40-60 doses depending on serving size)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Bioavailability: 13-19%

Why this matters for Bethel Census Area: The long duration is perfect for sustained relief during long winter nights or active summer days. The precise dosing lets you titrate carefully in a region where medical help may be hours away.

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900+ mg total cannabinoids
• Six cannabinoids (same ratio as sublingual, minus separate delta-9 listing because THCa auto-decarbs at vaping temperature)
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery)
• Duration: 2-4 hours
• Bioavailability: 10-35%

Why this matters for Bethel Census Area: When you’re dealing with breakthrough pain during a fishing trip or a panic attack in a remote location, 1-2 minute relief can be life-changing. The compact size fits easily in a pocket or dry bag.

When to Use Each Format

Use case	Recommended format	Rationale for Bethel Census Area
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset when you’re hours from medical help
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration covers long nights or active days
Maximum bioavailability	Sublingual	13-19% absorption maximizes limited supply
Portability and discretion	Vape	Compact for travel between villages or on the tundra
Precise dosing control	Sublingual	Graduated dropper essential in remote settings
Daytime non-psychoactive use	Sublingual (raw)	Operate boats, equipment, vehicles safely
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Seasonal affective disorder, insomnia relief

Condition-Specific Usage Context for Bethel Census Area

Important disclaimer: These contexts are informed by cannabinoid research cited in this document and by our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

For Bethel Census Area residents traveling to Anchorage or Seattle for cancer treatment:

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)

Evidence: delta-8 THC antiemetic [9], delta-9 THC nausea and vomiting evidence [1][13], CBD anxiolytic buffering [3]

Reality check: Many Bethel Census Area residents must travel for cancer treatment. Having a portable, legal option for nausea management during travel is valuable. But this complements medical care; it does not replace antiemetics prescribed by your oncologist.

Chronic Pain (Fishing Injuries, Arthritis, Neuropathy)

Chronic pain is widespread in Bethel Census Area due to physically demanding work in commercial fishing, construction, and subsistence activities:

• Daytime: 0.3-0.5 mL raw sublingual — anti-inflammatory support without impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset during active work

Evidence: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Alaska-specific consideration: The cold amplifies joint pain. The anti-inflammatory multi-pathway approach (CBD, CBG, THCa, caryophyllene) may be more effective than single-cannabinoid CBD products common in Alaska markets.

Sleep Support During Long Winter Nights

Seasonal affective disorder and disrupted circadian rhythms affect many in Bethel Census Area:

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN — the dosage level investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN — above the 20 mg threshold associated with reduced sleep disturbance in published research

Evidence: CBN sleep evidence [16][17], cannabis and sleep review literature

Important caveat: CBN’s sleep evidence is weaker than marketing suggests [16][17]. Some users report benefit, but it’s not clinically proven. Manage expectations accordingly.

Anxiety and Stress in Isolated Communities

Rural Alaska life, while beautiful, can be isolating and stressful:

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual — full profile including CBN for sleep architecture

Evidence: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

Community mental health context: Bethel Census Area has faced significant challenges with suicide, substance abuse, and mental health access. While our product may help manage anxiety symptoms, it is not a substitute for professional mental health care. Please reach out to local resources like the Yukon-Kuskokwim Health Corporation Behavioral Health Department or the Alaska Careline (1-877-266-4357) for serious mental health concerns.

General Titration Principle: Start Low, Go Slow

Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Remote setting caution: In Bethel Census Area, where emergency medical services may be delayed, conservative dosing is especially important. You can always take more; you can’t take less once it’s in your system.

Competitive Comparison: Why OilWell Stands Alone

OilWell RSO vs. Traditional RSO (What You Might Find in Alaska)

Dimension	Traditional RSO	OilWell RSO
Cannabinoid profile	THC-dominant, uncontrolled	7 cannabinoids at specific ratios
Terpenes	Destroyed by heat	Live terpenes at 5%
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Safety testing	Not performed	Full panel testing (pesticides, heavy metals, solvents, microbes)
Solvents	Naphtha/isopropyl risk	No solvents — formulated from pure distillates
Legal status	Illegal in Alaska (unless medical)	Farm Bill compliant, ships legally
Access	Black market only	Ships directly to Bethel Census Area
Potency control	Always psychoactive	You control activation

OilWell RSO vs. Alaska Medical Marijuana Program

Alaska has a medical marijuana program, but access is limited:

• Requires physician certification and state registration
• Limited dispensary locations (none in Bethel Census Area)
• Must travel to Anchorage or other urban centers
• Higher delta-9 THC content (which may be desirable for some but problematic for others)

OilWell offers:

• No medical card required (age 21+)
• Ships directly to your door in Bethel Census Area
• Lower delta-9 THC baseline with patient-controlled activation
• Multi-cannabinoid profile not available in Alaska medical dispensaries

Important: If you’re already enrolled in Alaska’s medical marijuana program, our products can complement your regimen but should not replace prescribed medications without consulting your physician.

The Evidence Behind Each Cannabinoid: What Science Says

CBD: The Most Studied Cannabinoid

Best supported evidence: Purified CBD has the strongest human evidence for seizure disorders, particularly rare epilepsies [1][2]. This is the clearest major indication acknowledged by institutional literature.

Anxiety: A 2024 systematic review and meta-analysis covering 316 participants across eight studies reported a statistically significant anxiolytic signal, but authors stressed that the clinical sample remains limited and more trials are needed [3].

Pain: A 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality limiting broad analgesic claims [4].

Sleep: A 2023 insomnia review found the literature methodologically weak, with many studies relying on nonvalidated subjective measures and few objective sleep assessments [5].

Safety concerns: A 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH also flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions [1].

Bottom line: CBD is the most evidence-developed nonintoxicating cannabinoid, but strong evidence is concentrated in specific indications rather than broad wellness claims [1]-[6].

CBG: The “Mother Cannabinoid”

Evidence profile: Mostly review-level and preclinical; human evidence remains sparse [7][8].

Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. It interacts with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A-related signaling — mechanistically interesting but not clinically established [7].

Potential areas: Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions [7][8].

Caution: A 2021 pharmacology review explicitly states that CBG is already being sold commercially while the evidence base remains thin, meaning claims frequently outrun the science [7].

Bottom line: CBG is a promising minor cannabinoid with limited clinical validation, not a proven therapeutic cannabinoid [7][8].

Delta-8 THC: Not “Weed Lite”

Evidence profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC [9]-[11].

Comparative pharmacology: A 2022 review concluded that delta-8 and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 is a partial CB1 agonist with cannabimimetic activity in animals and humans, but appears less potent than delta-9, likely due to weaker CB1 affinity [9].

Public health literature: A 2023 scoping review found the delta-8 evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong human trials. Reports of adverse consequences exist, and regulatory/product-quality concerns are emphasized [10].

Manufacturing context: Commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which raises product-byproduct and lab-testing questions [11].

Bottom line: Delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa: The Legal Distinction That Changes Everything

Evidence profile: Important chemically and formulation-wise, but low on direct human therapeutic evidence [12].

What it is: THCa is the acidic precursor of THC and represents a large share of THC-related content in raw plant material. It decarboxylates into THC during heating and can change over time during storage and processing [12].

Psychoactivity: THCa itself does not produce psychoactive effects associated with THC in humans, but this distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated [12].

Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].

Bottom line: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa must account for possible conversion into THC [12].

Delta-9 THC: The Most Studied Psychoactive Cannabinoid

Evidence profile: Strongest human evidence of psychoactive cannabinoids listed here, but also the clearest adverse-effect burden [1][13]-[15].

Best institutional support: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite/weight loss in HIV/AIDS, and some multiple sclerosis- and pain-related outcomes, while stressing many other uses remain uncertain [1].

Pain evidence: A 2022 systematic review found products with high THC content or comparable THC:CBD ratios may provide short-term pain benefit but also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].

Pharmacokinetics: Inhaled THC produces effects within seconds to minutes, peaks in 15-30 minutes, and tapers over a few hours. Oral THC has later onset, later peak, and longer duration [14].

Mental health risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression in nontherapeutic settings [15].

Broader safety: Includes anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns [1][14][15].

Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings but carries the clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].

CBN: The “Sleep Cannabinoid” With Weak Evidence

Evidence profile: Weak human evidence; marketing has moved ahead of the data [12][16][17].

Reputation: Sleep and sedation. That reputation is widespread, but clinical support is far thinner than marketing suggests [16][17].

Best sleep claim review: A 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims [16].

Broader sleep literature: A 2024 updated review concluded that overall cannabinoid sleep research still doesn’t match real-world use scale, and the need for better-designed, adequately powered trials remains substantial [17].

Bottom line: CBN is the clearest example where cultural reputation is stronger than current clinical evidence [16][17].

CBC: The Emerging Minor Cannabinoid

Evidence profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based [18][19].

Pharmacology: A 2024 focused review argues CBS has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].

Older literature: Anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims [19].

Safety caveat: The 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].

Bottom line: CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not in the category of already-validated clinical actives [18][19].

Terpenes: The Aromatic Dimension

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. The 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene: Citrus Brightness

Evidence profile: Largely review and preclinical, with useful safety literature [20]-[22].

Potential activity: A 2021 review describes limonene as a multifunctional monoterpenes with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but overwhelming share of claims comes from nonhuman or non-cannabis literature [21].

Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22].

Bottom line: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].

Myrcene: Earthy Depth

Evidence profile: Mostly preclinical, with very limited human evidence [20][23].

Research summary: The 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms but explicitly states that human studies are lacking [23].

Interpretation caution: Myrcene is often invoked as a proven sedating terpene that explains couch-lock or sleep effects. That is a stronger claim than human evidence currently supports [20][23].

Bottom line: Myrcene is a plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene: The CB2 Agonist

Evidence profile: Among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].

Why it stands out: A 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].

Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in review literature, but human clinical confirmation remains limited [24].

Bottom line: Beta-caryophyllene is arguably the strongest candidate for a terpene with cannabinoid-system significance, but it still should not be described as clinically proven for outcomes commonly attributed to it [24].

Pinene: Forest Fresh

Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25].

Brain-health framing: The 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study but emphasized that evidence is mostly preclinical and well-designed clinical trials are lacking [25].

Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].

Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool: Floral Calm

Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation

---